BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Metastatic Solid Tumor|Hormone-receptor-positive Breast Cancer|Breast Cancer|Metastatic Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|HER2-negative Breast Cancer
Interventions: DRUG: BGB-43395|DRUG: Fulvestrant|DRUG: Letrozole
Sponsor: BeiGene